Three Pivotal Drug Policy Organizations Hold Media Briefing/Q&A on DEA Rescheduling of Cannabis
2024年5月2日 - 6:54AM
What: The Multidisciplinary Association for
Psychedelic Studies (MAPS), The Marijuana Policy Project (MPP), and
the National Organization for the Reform of Marijuana Laws (NORML)
- three of the most pivotal drug policy reform organizations in the
United States - will host a roundtable discussion/Q&A for the
media on the news that, on the recommendation of the Department of
Health & Human Services (HHS), the Drug Enforcement
Administration (DEA) has proposed rescheduling cannabis from a
Schedule I drug to a Schedule III drug. If implemented following a
rulemaking process, this unprecedented federal drug policy change
could provoke reforms across many areas of marijuana-related laws.
MAPS has assembled leaders with more than 50 years of combined
experience in the cannabis policy reform movement to talk about
what these changes are, why they matter, what myths need debunking,
and what still needs to be done.
Who:Moderator - Betty
Aldworth, Director of Communications &
Post-Prohibition Strategy and long time drug policy reform
advocateGuest - Karen O’Keefe -
Director of State Policies at Marijuana Policy Project
(MPP)Guest - Paul Armentano -
Deputy Director, NORML
Topics will include potential impacts on:
- Research & development for cannabis-based medicines
- Criminal law and systems-impacted people
- Cannabis business banking or interstate commerce
- Veterans Affairs and Veterans
- …and what’s next?
Where/When: Thursday, May 2, 202411:00 AM
ET
Register online:
https://us02web.zoom.us/webinar/register/WN_2Rot6b4pQ26F6MQXgo4hTQ
Accredited media only. Questions may be directed
to maps@kcsa.com.
Why:Cannabis has been a substance of interest
for MAPS since its inception in 1986. Cannabis sits squarely in the
MAPS mission that envisions “a world where psychedelics and
marijuana are safely and legally available for beneficial uses, and
where research is governed by rigorous scientific evaluation of
their risks and benefits.” Most recently in 2021, MAPS was awarded
a $12.9M grant from Michigan to research inhaled cannabis for
symptoms of PTSD among Veterans.
In August of 2023, the HHS provided a recommendation to the DEA
recommending that the DEA reschedule cannabis from Schedule I to
Schedule III. The DEA’s proposal was circulated on Tuesday April
30, and it serves as a moment in time where the media will be
looking for informed sources and validated facts to talk about the
future of cannabis in America.
Contact:maps@kcsa.com
ABOUT MAPSFounded in 1986,
MAPS is a 501(c)(3) nonprofit research and educational organization
that develops medical, legal, and cultural contexts for people to
benefit from the careful uses of psychedelics and marijuana. MAPS
previously sponsored the most advanced psychedelic-assisted therapy
research in the world and continues to support psychedelic and
marijuana research with a focus on the people and places most
impacted by trauma. MAPS incubated Lykos Therapeutics, a
drug-development public benefit company, and The Zendo Project, a
leader in psychedelic harm reduction. Since MAPS was founded,
philanthropic donors and grantors have given more than $150 million
to advance psychedelic research, change drug policy, and shape
culture.